Amgen drug Sensipar fails to meet trial goal
The goal of the study was to show a reduction in the risk of death, heart attack, unstable angina or heart failure in patients with chronic kidney disease who were receiving dialysis. Although patients taking Sensipar experienced fewer events, ...
Amgen Says Recent Sensipar Study Failed to Meet Primary Endpoint
Amgen Reports Top-Line Results Of Phase 3 Sensipar/Mimpara EVOLVE Trial